Compare Ginkgo Bioworks Holdings Inc (DNA) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Koninklijke Philips NV — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.78 (market cap $763.64M), while Koninklijke Philips NV trades at $24.32 (market cap $23.52B). The key difference: Koninklijke Philips NV is far larger — about 30.8× Ginkgo Bioworks Holdings Inc's market cap, and Koninklijke Philips NV pays a 4.17% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Koninklijke Philips NV for 84 Days on average.
| DNA | PHG | |
|---|---|---|
Market Cap | $763.64M | $23.52B |
Volume | 3,204,177 | 1,635,069 |
Sector | Health | Health |
52-Week High | $15.83 | $32.91 |
52-Week Low | $5.48 | $23.81 |
Typical Hold Time | 7 Days | 84 Days |
Enterprise Value | $865.59M | $29.87B |
Dividend Yield | — | 4.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% today, reflecting ongoing volatility. The stock shows a bullish technical signal with strong moving average support, but fundamentals reveal significant challenges: revenue declined to $170.16M in 2025 with a net loss of $312.76M, and negative cash flow persists. Recent news includes a partnership with TuneLab for AI-driven drug discovery and a $17.5M ARPA-H subcontract for RNA medicine manufacturing, indicating strategic growth initiatives amid financial headwinds.
The outlook remains high-risk due to persistent losses and cash burn, though analyst sentiment is split evenly between buy, hold, and sell. Upside potential hinges on successful commercialization of its platform and cost management, while downside risks include execution missteps and prolonged profitability challenges. Investors should weigh the company's innovative partnerships against its weak financial metrics.
PHG trades at $24.09, down 0.25% with a bearish technical signal. The company shows improving fundamentals with three consecutive quarterly EPS beats and a return to profitability in 2025 (net income $895M). Recent news highlights innovation in healthcare technology including new product launches and AI partnerships. Valuation metrics appear reasonable with P/E of 18.94 and P/S of 1.18.
PHG presents a mixed outlook with strong operational recovery but technical weakness. The investment case hinges on continued earnings momentum and successful execution of healthcare technology initiatives. Key risks include competitive pressures and potential cybersecurity vulnerabilities following recent hacking incidents. Analyst consensus leans neutral with 36% buy ratings versus 64% hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
